Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
552 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 95 | MacroGenicsINDUSTRY | 5 | Mar 17, 2025 | clinicaltrials |
| NCT03165955 | A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients | completed | Phase 1 | 28 | Health Hope PharmaINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05166577 |
| Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC |
| terminated |
| Phase 1 |
| 26 |
| Viracta Therapeutics, Inc.INDUSTRY |
| 8 |
| Mar 12, 2025 |
| clinicaltrials |
| NCT05514496 | A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer | active not recruiting | Phase 1 | 258 | Nalo Therapeutics Inc.INDUSTRY | 3 | Mar 11, 2025 | clinicaltrials |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 7 | Great Novel Therapeutics Biotech & Medicals CorporationINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | terminated | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Jan 28, 2025 | clinicaltrials |
| NCT01121588 | Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) | terminated | Phase 1 | 44 | PfizerINDUSTRY | 7 | Jan 23, 2025 | clinicaltrials |
| NCT06071013 | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | recruiting | Phase 1 / Phase 2 | 20 | China Medical University HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT05281276 | Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | terminated | Phase 1 | 9 | Taipei Medical University Shuang Ho HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer(ARC-4) | completed | Phase 1 | 77 | Arcus Biosciences, Inc.INDUSTRY | 4 | Dec 9, 2024 | clinicaltrials |
| NCT06723964 | A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors | active not recruiting | Phase 1 | 35 | AP Biosciences Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT03812874 | A Study of PTX-9908 Injection for Non-resectable HCC with TACE | recruiting | Phase 1 / Phase 2 | 50 | TCM Biotech International Corp.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02699515 | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 114 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT05156203 | Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | recruiting | Phase 1 | 30 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05983523 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 54 | PharmaEngineINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT03799003 | A Study of ASP1951 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 119 | Astellas Pharma Global Development, Inc.INDUSTRY | 4 | Nov 1, 2024 | clinicaltrials |
| NCT02038673 | An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | completed | Phase 1 | 86 | Astellas Pharma IncINDUSTRY | 4 | Oct 31, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | terminated | Phase 1 / Phase 2 | 409 | PfizerINDUSTRY | 8 | Jul 30, 2024 | clinicaltrials |
| NCT04807257 | Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment | recruiting | Phase 1 / Phase 2 | 18 | NanoRay Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | terminated | Phase 1 / Phase 2 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT02318329 | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | completed | Phase 1 | 79 | Five Prime Therapeutics, Inc.INDUSTRY | 3 | Jun 4, 2024 | clinicaltrials |
| NCT04580121 | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | completed | Phase 1 | 59 | Hoffmann-La RocheINDUSTRY | 10 | Jun 3, 2024 | clinicaltrials |
| NCT04250597 | Study of GNX102 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 46 | GlycoNex, Inc.INDUSTRY | 2 | May 6, 2024 | clinicaltrials |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 600 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | May 3, 2024 | clinicaltrials |
| NCT04281420 | A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma(TEACH) | terminated | Phase 1 | 20 | Antengene Therapeutics LimitedINDUSTRY | 2 | Apr 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials